# Leqembi launched in India for early Alzheimer’s after CDSCO approval 2026-08-06T19:55:17+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet Eisai has launched Leqembi, or lecanemab, in India for patients with mild cognitive impairment and mild dementia caused by early Alzheimer’s disease, after receiving marketing authorisation from the Central Drugs Standard Control Organisation. The company describes it as India’s first disease-modifying therapy for the condition. Patients must first undergo testing for amyloid pathology through cerebrospinal fluid or serum biomarkers. Eisai said access could be limited by the cost of treatment, gaps in early diagnosis, biomarker testing, infusion facilities and reimbursement. Estimates cited from the AIIMS-USC LASI study put India’s dementia burden among people aged 60 and above at 8.8 million in 2023, with the number projected to nearly double by 2036. ## Coverage - thehindu.com Tags: Alzheimer’s disease, CDSCO, dementia, Eisai, Leqembi Canonical: https://indianopinion.org/leqembi-launched-in-india-for-early-alzheimers-after-cdsco-approval/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/leqembi-launched-in-india-for-early-alzheimers-after-cdsco-approval/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.